Literature DB >> 15319416

Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice.

Malgorzata Milkiewicz1, Christopher W Pugh, Stuart Egginton.   

Abstract

Hypoxia-inducible factor (HIF) modulates transcriptional control of several genes involved in vascular growth and cellular metabolism. HIF activity can be enhanced by suppression of prolyl and asparaginyl hydroxylase activity by dimethyloxalylglycine (DMOG). We have compared the effects of DMOG treatment and femoral artery ligation individually or in combination on HIF-1alpha protein level, HIF-dependent gene expression and capillary-to-fibre ratio (C: F) in extensor digitorum longus and tibialis anterior muscles of mice. Immunohistochemical examination revealed that HIF-1alpha is present in non-ischaemic mouse skeletal muscles, but its amount increased profoundly in response to the combination of DMOG treatment and ischaemia. Combined treatment resulted in 39% increase in C: F in ischaemic muscles (P < 0.0001 versus controls) whereas individual treatments produced little effect under our conditions. Combined treatment led to a significant increase in endogenous HIF-1alpha protein (6.14 +/- 1.1 versus 1.17 +/- 0.2 in controls; P < 0.05) that was not apparent in mice treated with DMOG or femoral artery ligation alone. Ischaemia increased vascular endothelial growth factor (VEGF) protein production by 2.5-fold (P < 0.05 versus controls), irrespective of DMOG treatment. However, production of the VEGF receptor Flk-1 was more enhanced in ischaemic + DMOG-treated muscles (P < 0.001 and P < 0.05 compared with controls and untreated ischaemic muscles, respectively), which may explain the intensive growth of capillaries in those muscles. The findings indicate that treatment with DMOG has a potential therapeutic use in promoting angiogenesis in ischaemic diseases, and perhaps for improving muscle recovery after injury, exercise or training.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319416      PMCID: PMC1665195          DOI: 10.1113/jphysiol.2004.069757

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  18 in total

1.  PR39, a peptide regulator of angiogenesis.

Authors:  J Li; M Post; R Volk; Y Gao; M Li; C Metais; K Sato; J Tsai; W Aird; R D Rosenberg; T G Hampton; F Sellke; P Carmeliet; M Simons
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

2.  HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia.

Authors:  D M Stroka; T Burkhardt; I Desbaillets; R H Wenger; D A Neil; C Bauer; M Gassmann; D Candinas
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

3.  Transcription. Oxygen sensing gets a second wind.

Authors:  Richard K Bruick; Steven L McKnight
Journal:  Science       Date:  2002-02-01       Impact factor: 47.728

Review 4.  Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease.

Authors:  G L Semenza
Journal:  Pediatr Res       Date:  2001-05       Impact factor: 3.756

5.  Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat.

Authors:  Kou Gi Shyu; Mei Ti Wang; Bao Wei Wang; Chih Chuna Chang; Jyh Gang Leu; Peiliang Kuan; Hang Chang
Journal:  Cardiovasc Res       Date:  2002-06       Impact factor: 10.787

6.  Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor.

Authors:  K A Vincent; K G Shyu; Y Luo; M Magner; R A Tio; C Jiang; M A Goldberg; G Y Akita; R J Gregory; J M Isner
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

7.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

8.  The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.

Authors:  T Takahashi; M Shibuya
Journal:  Oncogene       Date:  1997-05-01       Impact factor: 9.867

9.  Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway.

Authors:  Chan-Hyung Kim; Young-Suk Cho; Yang-Sook Chun; Jong-Wan Park; Myung-Suk Kim
Journal:  Circ Res       Date:  2002-02-08       Impact factor: 17.367

10.  Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis.

Authors:  Carsten Willam; Norma Masson; Ya-Min Tian; S Aleema Mahmood; Michael I Wilson; Roy Bicknell; Kai-Uwe Eckardt; Patrick H Maxwell; Peter J Ratcliffe; Christopher W Pugh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

View more
  61 in total

1.  Physiological angiogenesis is a graded, not threshold, response.

Authors:  Stuart Egginton; Iman Badr; James Williams; David Hauton; Guus C Baan; Richard T Jaspers
Journal:  J Physiol       Date:  2010-11-08       Impact factor: 5.182

2.  A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Bioconjug Chem       Date:  2019-04-01       Impact factor: 4.774

3.  Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.

Authors:  Kristen A Wieghaus; Erwin P Gianchandani; Milton L Brown; Jason A Papin; Edward A Botchwey
Journal:  Tissue Eng       Date:  2007-10

Review 4.  Invited review: activity-induced angiogenesis.

Authors:  Stuart Egginton
Journal:  Pflugers Arch       Date:  2008-08-13       Impact factor: 3.657

5.  Engineering vascularized tissues using natural and synthetic small molecules.

Authors:  Lauren S Sefcik; Caren E Petrie Aronin; Edward A Botchwey
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

6.  Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis.

Authors:  Yukiji Takeda; Sandra Costa; Estelle Delamarre; Carmen Roncal; Rodrigo Leite de Oliveira; Mario Leonardo Squadrito; Veronica Finisguerra; Sofie Deschoemaeker; Françoise Bruyère; Mathias Wenes; Alexander Hamm; Jens Serneels; Julie Magat; Tapan Bhattacharyya; Andrey Anisimov; Benedicte F Jordan; Kari Alitalo; Patrick Maxwell; Bernard Gallez; Zhen W Zhuang; Yoshihiko Saito; Michael Simons; Michele De Palma; Massimiliano Mazzone
Journal:  Nature       Date:  2011-10-09       Impact factor: 49.962

7.  HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.

Authors:  Daniel A Tennant; Eyal Gottlieb
Journal:  J Mol Med (Berl)       Date:  2010-04-11       Impact factor: 4.599

8.  Dimethyloxaloylglycine increases the bone healing capacity of adipose-derived stem cells by promoting osteogenic differentiation and angiogenic potential.

Authors:  Hao Ding; You-Shui Gao; Yang Wang; Chen Hu; Yuan Sun; Changqing Zhang
Journal:  Stem Cells Dev       Date:  2014-01-24       Impact factor: 3.272

9.  Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.

Authors:  Jonathan E Sears; George Hoppe; Quteba Ebrahem; Bela Anand-Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-04       Impact factor: 11.205

10.  Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

Authors:  Massimiliano Mazzone; Daniela Dettori; Rodrigo Leite de Oliveira; Sonja Loges; Thomas Schmidt; Bart Jonckx; Ya-Min Tian; Anthony A Lanahan; Patrick Pollard; Carmen Ruiz de Almodovar; Frederik De Smet; Stefan Vinckier; Julián Aragonés; Koen Debackere; Aernout Luttun; Sabine Wyns; Benedicte Jordan; Alberto Pisacane; Bernard Gallez; Maria Grazia Lampugnani; Elisabetta Dejana; Michael Simons; Peter Ratcliffe; Patrick Maxwell; Peter Carmeliet
Journal:  Cell       Date:  2009-02-12       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.